Top Qs
Timeline
Chat
Perspective

Pegfilgrastim

Monoclonal antibody From Wikipedia, the free encyclopedia

Remove ads

Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.[20] It serves to stimulate the production of white blood cells (neutrophils).[20][22] Pegfilgrastim was developed by Amgen.[23]

Quick Facts Clinical data, Trade names ...

Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.[24]

Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).[25][24]

Pegfilgrastim was approved for medical use in the United States in January 2002, in the European Union in August 2002, and in Australia in September 2002.[23][21][26][27][28] It is on the World Health Organization's List of Essential Medicines.[29]

Remove ads

Medical uses

Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in people with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia; and to increase survival in people acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome).[20][30][31]

Remove ads

Society and culture

In January 2025, the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Dyrupeg, intended to shorten the duration of neutropenia and help prevent febrile neutropenia after cytotoxic chemotherapy.[5] The applicant for this medicinal product is CuraTeQ Biologics s.r.o.[5] Dyrupeg is a biosimilar medicinal product that is highly similar to the reference product Neulasta, which was authorized in the EU in August 2002.[5] Dyrupeg was authorized for medical use in the European Union in March 2025.[5][32]

In June 2025, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vivlipeg, intended to reduce the duration of neutropenia and the incidence of febrile neutropenia after cytotoxic chemotherapy.[33] The applicant for this medicinal product is Biosimilar Collaborations Ireland Limited.[33] Vivlipeg is a biosimilar medicinal product that is highly similar to Neulasta.[33]

Remove ads

References

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads